丙型肝炎病毒感染的肿瘤学负担:临床视角
慢性丙型肝炎病毒(HCV)感染影响全球数百万人且与癌症相关,直接抗病毒药物(DAA)已改变HCV治疗模式,但癌症患者的HCV管理所知甚少。作者复习文献并提出推荐:血液系统恶性肿瘤患者、造血细胞移植候选者和肝癌患者应筛查HCV;对其他癌症患者至少可考虑筛查高危人群;有HCV感染证据者应由专家评估肝病严重程度、合并症和治疗机会;DAA治疗应根据患者预后、癌症类型、癌症治疗计划和肝脏及病毒学参数制定;伴肝硬化的HCV感染癌症患者应持续随访以及时发现和治疗肝细胞癌;HCV感染及其治疗不应视为癌症治疗的禁忌,也不应延误紧急癌症治疗的启动。
要点
- 血液系统恶性肿瘤患者、造血细胞移植候选者和肝癌患者推荐筛查HCV。
- 其他癌症患者至少可考虑筛查高危人群,包括1945年至1965年出生者及感染高危者。
- HCV感染及其治疗不应视为癌症治疗禁忌,也不应延误紧急癌症治疗。
核心结论
- HCV感染及其治疗不应视为癌症治疗的禁忌证,也不应延误紧急癌症治疗的启动。
- 伴肝硬化(或甚至晚期纤维化)及有肝病进展风险的HCV感染癌症患者应持续随访,无论是否获得持续病毒学应答,以确保及时检出和治疗肝细胞癌。
研究设计与样本
- 作者复习文献并制定推荐,发表于CA Cancer J Clin 2017;67:411-431。
主要发现
- 推荐筛查HCV的患者包括所有血液系统恶性肿瘤患者、造血细胞移植候选者和肝癌患者。
- 对其他类型癌症患者缺乏识别HCV感染者的共识性推荐,但医生至少可考虑筛查HCV感染高危人群,包括1945年至1965年出生者及感染高危者。
- 有HCV感染证据的患者应由专家评估肝病严重程度、HCV感染相关合并症和治疗机会。
- DAA治疗应根据患者预后、癌症类型、癌症治疗计划以及肝脏和病毒学参数制定。
- 伴肝硬化(或甚至晚期纤维化)及有肝病进展风险(尤其伴HCV相关合并症)的HCV感染癌症患者应持续随访,无论是否获得持续病毒学应答,以确保及时检出和治疗肝细胞癌。
临床怎么用
- 血液系统恶性肿瘤患者、造血细胞移植候选者和肝癌患者推荐筛查HCV。
- 其他癌症患者医生至少可考虑筛查HCV感染高危人群,包括1945年至1965年出生者及感染高危者。
- 有HCV感染证据者应由专家评估肝病严重程度、HCV相关合并症和治疗机会。
- DAA治疗应根据患者预后、癌症类型、癌症治疗计划以及肝脏和病毒学参数制定。
- HCV感染及其治疗不应视为癌症治疗禁忌,也不应延误紧急癌症治疗的启动。
局限性
- 关于癌症患者HCV感染的检测和管理证据尚不确凿。
- 对其他类型癌症患者缺乏识别HCV感染者的共识性推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Answer questions and earn CME/CNE Chronic hepatitis C virus (HCV) infection affects millions of people worldwide and is associated with cancer. Direct-acting antivirals (DAAs) have changed HCV treatment paradigms, but little is known about the management of HCV infection in patients with cancer. The substantial burden of HCV infection and the inconclusive evidence regarding its detection and management in patients with cancer prompted the authors to review the literature and formulate recommendations. Patients for whom HCV screening is recommended included all patients with hematologic malignancies, hematopoietic cell transplantation candidates, and patients with liver cancer. There is a lack of consensus-based recommendations for the identification of HCV-infected patients with other types of cancer, but physicians may at least consider screening patients who belong to groups at heightened risk of HCV infection, including those born during 1945 through 1965 and those at high risk for infection. Patients with evidence of HCV infection should be assessed by an expert to evaluate liver disease severity, comorbidities associated with HCV infection, and treatment opportunities. DAA therapy should be tailored on the basis of patient prognosis, type of cancer, cancer treatment plan, and hepatic and virologic parameters. HCV-infected patients with cancer who have cirrhosis (or even advanced fibrosis) and those at risk for liver disease progression, especially patients with HCV-associated comorbidities, should have ongoing follow-up, regardless of whether there is a sustained virologic response, to ensure timely detection and treatment of hepatocellular carcinoma. HCV infection and its treatment should not be considered contraindications to cancer treatment and should not delay the initiation of an urgent cancer therapy. CA Cancer J Clin 2017. © 2017 American Cancer Society. CA Cancer J Clin 2017;67:411-431. © 2017 American Cancer Society.
引用
- Torres HA, Shigle TL, Hammoudi N, et al. The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin. 2017. PMID: 28683174. doi:10.3322/caac.21403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。